What's Happening?
Vivos Inc., a medical device company specializing in Precision Radionuclide Therapy™ for cancer treatment, has received a Washington State Radioactive Materials License for manufacturing IsoPet®. This license allows Vivos to produce IsoPet® at its new
facility in Richland, Washington, marking a significant regulatory milestone. IsoPet® is a non-invasive cancer therapy for animals, delivering a high dose of Yttrium-90 directly into tumors. The company plans to apply for an amendment to include RadioGel® in the license, supporting clinical trials in the U.S. and internationally.
Why It's Important?
The acquisition of this license is crucial for Vivos as it enables the company to establish domestic manufacturing capabilities, ensuring a reliable supply of IsoPet® to meet growing demand. This development is expected to enhance the company's ability to expand its network of certified treatment centers across the U.S., providing more pet owners and veterinarians access to innovative cancer therapies. The move also positions Vivos to potentially expand its market presence and increase its share in the veterinary oncology sector.
What's Next?
With the license secured, Vivos plans to commence its first production run soon, facilitating the expansion of IsoPet® treatment centers nationwide. The company will also pursue an amendment to include RadioGel® in the license, which could lead to broader clinical applications and potential international trials. These steps are part of Vivos's strategy to scale production and enhance its market position in the animal health industry.
